CYP19A1 and breast cancer: The underlying cause of the metabolic alterations including changes in glucose and insulin metabolism is not clear and are most likely only part of the metabolic changes occurring as a consequence of adjuvant chemotherapy and/or aromatase inhibitors of BC patients.